Patent Office Says, “Have It Your Way!” For A Price.

The PTO has proposed a “Three-Track Examination” option for applicants which gives them the opportunity to jump to the head of the examination line (goal: 12 mo. pendency  with first office action within two months) or to put the application on hold for up to 30 months (note to file: how can an applicant tell he/she is on this path?). The third choice is to do nothing. The program applies to applications that have not been refiled. Applications claiming foreign priority would have to apply with a search report, first official action, and a response in hand. But there are no such requirements for U.S. applicants, except possibly a limitation on the number and type of claims (to be decided). This is a lot less onerous than the requirements for accelerated examination, which require a search report, a summary of the art, etc., and the fast-tracking of applications on “Green Technology.” Both have been little used to date.

I am typing this during a break from doing interviews at the PTO (four today) and, concerns about discrimination against “foreign” applicants aside, I am for it. One of the applications I am interviewing was filed in the U.S. via a PCT in 2001. (I recently inherited this application.) The average time between (non-final) office actions has been about seven months, with a series of Examiners. Right now, it is entitled to over 1000 days of PTA. Believe me, I have a search report from the priority country. Would the client, a small pharma company, pay to speed this up with a goal of resolution in any preselected time? You betcha!

Posted in USPTO Practice and Policy | Tagged , , , , | Leave a comment

ISC Patent On Making Human Stem Cells Advances Cloning Technology

 

Apart from being praised as an ethical work-around to the problems of destroying early-stage human embryos—often about to be discarded as surplusage by fertility clinics — to obtain human pluripotent stem cells, Revazova et al. (U.S. Pat. No. 7732202 – copy at end of post) got relatively little attention from the IP community. I predict that the relatively benign reception that this patent got will change as various groups begin to sort through the claims and 138 columns of disclosure. Dolly, the cloned ewe, was made by removing the nucleus from an oocyte, or unfertilized ovum, of one breed of sheep, and replacing it with nuclear material from an adult donor cell taken from a different breed of sheep. The renucleated oocyte was induced to divide by an electrical pulse, and reimplanted in a surrogate mother, that eventually gave birth to Dolly, who looked just like the sheep that donated the nuclear material. The donor sheep had successfully been cloned. Today you can clone Fluffy, your favorite cat or, if the USDA would allow it, eat a burger made from beef from a cloned herd of steers. In 1998, Tompson et al. at the University of Wisconsin, claimed human embryonic stem cells obtained by disassembling blastocysts, or very early stage fertilized eggs. In 83 JPTOS 830 (Nov. 2001), I wrote:

“The debate about reproductive or therapeutic cloning of individuals has become interlocked with the ethical controversy that has accompanied a new area of science broadly termed “stem cell technology.” This area of research is based on the discovery that cells of the early mammalian embryo, including those from the blastocyst, can be cultured in vitro so as to proliferate indefinitely in an undifferentiated state. More importantly, the cells are pluripotent, in that they can be induced by various cytokines to form derivatives of all three embryonic germ layers. These “[embryonic] stem cells” (ES) have enormous potential for both drug discovery and direct therapeutic applications….Combined with cloning techniques, the use of ES theoretically permits an individual to clone him/herself in early embryonic form in order to obtain and differentiate stem cells into tissue that could be used for an autologous transplant, …or even to create synthetic organs.”

Continue reading

Posted in Stem Cells/Cloning | Tagged , , , , , , , , , , | Leave a comment

DNA As Information. “Synthetic Genome” Paper Brings New Life To Old Debate

In the landmark paper by Gibson, Smith, Venter et al, Science Express (May 20, 2010), reporting the successful replacement of one bacterial genome by a completely synthetic, functional chromosome,  the authors note: “This work provides a proof of principle for producing cells based on genome sequences designed in the computer. DNA sequencing of a cellular genome allows storage of the genetic instructions for life as a digital file.” But is the file patentable? In her introduction to the paper in Science, 328, 958 (May 21, 2010) Elizabeth Pennisi employs a software analogy as well when she describes how the group overcame early failures in getting the synthetic genome to function in its new home: “Like computer programmers debugging faulty software, they systematically transplanted combinations of synthetic and natural DNA, finally homing in on a single -base mistake in the synthetic genome.” [Note to file: At last, a patentable SNP!]

Analogies like these are going to re-awaken the debate about how to resolve the conflict between permitting patents of DNA molecules as tangible chemical entities (“An isolated, purified DNA molecule of SEQ ID NO:!”) and permitting patents on DNA sequences as information storage media (e.g., “A computer readable medium having recorded thereon the nucleotide sequence depicted in SEQ ID NO:1”).   In “Locating Gene Patents within the Patent System”, American J. Bioethics, 2, 18 (2002), Arti K Rai concluded:

 “Given that in the future the primary usefulness of DNA sequences may lie in their in silico (as contrasted with in vitro) representations, limiting patents to the biological molecule may inappropriately curtail the scope of protection available in drug development. By the same token, if we are going to allow widespread patenting of information in computer readable form-as we have apparently decided to do -the need for some type of fair use law becomes even more important.”

Ms. Rai’s article was one of a series of solicited “Open Peer Commentaries” (including one by me) on a longer article by Rebecca S. Eisenberg in the same issue, “How Can You Patent Genes?” The Myriad lawsuit and Bilski v. Kappos must have been visible in her tea leaves when she wrote the introduction: “The patenting system has built for a ‘bricks and mortar’ world rather than an information economy. The fact that genes are both material molecules and informational systems helps explain the difficulty that the patent system in going to continue to have.”

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment

VENTER GROUP LABELS SYNTHETIC LIFE “PAT. PENDING”

In the May 20th issue of Science Express, a group led by Daniel Gibson, Hamilton Smith and  J. Craig Venter published an article that got the full attention of scientists, bioethicists and IP attorneys worldwide: “Creation of a Bacterial Cell Controlled by a Chemically-Synthesized Gene. “ The methodology employed was well summarized by Elizabeth Pennisi in her introduction to the paper: “Synthetic Genome Brings New Life to Bacterium” (Science, 328, 958 (May 21, 2010)) and in the article itself, as well as by patentdocs.org, and so does not need undue replication here.

After the Venter group was able to successfully transfer the entire genome (one chromosome, in this case) of a simple bacterium to another related species, and demonstrated that they could synthesize an artificial chromosome that was labeled so it could be tracked, the group set about to synthesize the 1-million-base genome of the bacterium M. mycoides and transfer it into the related species M. capricolum. The starting-point sequence was available online (no patent problems there, Judge Sweet), so the group bought one thousand 1080-base sequences from a DNA-on-demand company and set about to assemble them into “a completely assembled synthetic genome.” (Note to file: How did the group select the individual 1080 base sequences they ordered? See US 2010/0041035 A1.)

A functional yeast clone was obtained and transplanted into M. capricolum. The synthetic genome was “watermarked” with preselected unique sequences so the group could tell it was “theirs”. Using a conventional marker gene allowed them to identify functional transformed bacteria that contained the synthetic chromosome, which they further characterized by sequencing and protein profiling. (Note to file: Use Fig. 1 of the Science paper to train junior biotech associates in modern transgenic methodologies.)

 Although Ms. Pennisi states that commentators “emphasize that this work didn’t create a truly synthetic life form, because the genome was put into an existing cell,” Venter et al. are not quite so restrained. To quote from the Science paper:

 “We refer to such a cell controlled by a genome assembled from chemically synthesized pieces of DNA as a ‘synthetic cell’ even though the cytoplasm of the recipient cell is not synthetic [Note to file; neither is the cell wall]. Phenotypic effects of the recipient cytoplasm are diluted with protein turnover and as cells carrying only the transplanted genome replicate. Following transplantation [of the synthetic genome] and replication on a plate to form a colony…progeny will not contain any protein molecules that were present in the original recipient cell….The properties of the [progeny] cells controlled by the synthetic genome are expected to be the same as if the whole cell had been produced synthetically (the DNA software builds its own hardware). “

 A quick search for published patent applications directed to this feat (and its future) yielded Venter et al., published application US 2007/0264688 A1 (Nov. 15, 2007). Here are a few representative claims:

1. A method for constructing a synthetic genome comprising:

assembling nucleic acid cassettes that comprise portions of the synthetic genome, where at least one of the nucleic acid

cassettes is constructed from nucleic acid components that have been chemically synthesized, or from copies of chemically-

synthesized nucleic acid components.

 

2. The method of claim 1, wherein the genome is a non-naturally occurring genome.

 

14.  The method of claim 1, wherein an entire synthetic genome is constructed from nucleic acid components that have been chemically synthesized,

or from copies of the chemically synthesized nucleic acid components.

 

32.  A synthetic genome.

 

34. A synthetic cell comprising a synthetic genome.

 

38. A method comprising:

designing a synthetic genome;

constructing the synthetic genome;

introducing the synthetic genome into a biological system; and

expressing said genome.

 

How’s that for a glimpse into the future of “patenting life”?

Posted in Stem Cells/Cloning | Tagged , , | Leave a comment